Processa Pharmaceuticals, Inc. PCSA
1.56 USD -0.13 (-7.69%)
Regular-session close
1.59 +0.03 +1.92%
After hours · Nov 20, 4:00 PM ET
1.39 Day range 1.66
1.04 52-week range 8.88
- YTD
- -45.83%
- 1 year
- -77.13%
News
seekingalpha.com Processa Pharmaceuticals, Inc. (PCSA) Presents at UBS Global Biopharma Conference 2026 Transcript Processa Pharmaceuticals, Inc. (PCSA) Presents at UBS Global Biopharma Conference 2026 Transcriptbenzinga.com Processa Pharmaceuticals Appoints Gregory J. Flesher Operations Chief Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company advancing differentiated therapeutic programs for immunological and inflammatory
benzinga.com Processa Pharmaceuticals Announces FDA Clears Its Investigational New Drug Application For Phase 2 Trial Of VT-7208 In Chronic Spontaneous Urticaria Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company developing VT-7208, a Bruton's tyrosine kinase (BTK) inhibitor therapy for
